Literature DB >> 10564558

Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL).

M O Moraes1, E N Sarno, A S Almeida, B C Saraiva, J A Nery, R C Martins, E P Sampaio.   

Abstract

Leprosy patients during the natural course of the disease may develop reactional episodes, namely reversal reaction (RR) and erythema nodosum leprosum (ENL). Immunological events described as occurring during RR indicate up-regulation of the immune response, whereas in ENL the events are not fully understood. The aim of this study was to analyse the in vivo pattern of cytokine gene expression in the reactional states of leprosy. Peripheral blood mononuclear cells (PBMC, n = 14) and tissue samples (n = 17) obtained from patients with ENL and RR were obtained and assayed by RT-PCR. PBMC obtained from unreactional patients (n = 15) and normal individuals (n = 5) were also assessed. Expression of interferon (IFN)gamma, granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin (IL)-2Rp55, perforin and IL-1beta mRNA in PBMC were detected mostly in ENL/RR patients, but not in unreactional patients. Likewise, cytokines such as IL-6, IL-8, tumour necrosis factor (TNF)alpha and TNFbeta were also present in reactional and tuberculoid patients as opposed to lepromatous leprosy (BL/LL). Interestingly, the majority of ENL/RR patients showed messages for IL-6, IL-10, IL-12 and TNFalpha in the skin. IFNgamma was detected in 84.6% (ENL) and 100% (RR) of the patients, whereas IL-4 was detected only in few individuals (38.5 and 25%, respectively). Although mRNA expression and protein levels may be different, the data reported in this study suggest a cytokine mRNA profile that seems to be indistinguishable for RR and ENL. In addition, it shows up-regulation of immuno-inflammatory cytokines in the blood and tissue of the same patient examined before and during reaction. Furthermore, it is suggested that this pattern of response results from an immunological reactivation that might lead to an acute inflammatory response in both reactional episodes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10564558     DOI: 10.1046/j.1365-3083.1999.00622.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  27 in total

1.  Effects of prednisolone treatment on cytokine expression in patients with leprosy type 1 reactions.

Authors:  Anna K Andersson; MeherVani Chaduvula; Sara E Atkinson; Saroj Khanolkar-Young; Suman Jain; Lavanya Suneetha; Sujai Suneetha; Diana N J Lockwood
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

2.  Induction of apoptosis in monocytes by Mycobacterium leprae in vitro: a possible role for tumour necrosis factor-alpha.

Authors:  M O Hernandez; I Neves; J S Sales; D S Carvalho; E N Sarno; E P Sampaio
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

3.  Increased CXC ligand 10 levels and gene expression in type 1 leprosy reactions.

Authors:  David M Scollard; Meher V Chaduvula; Alejandra Martinez; Natalie Fowlkes; Indira Nath; Barbara M Stryjewska; Michael T Kearney; Diana L Williams
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

4.  The role of indoleamine 2, 3-dioxygenase in lepromatous leprosy immunosuppression.

Authors:  J de Souza Sales; F A Lara; T P Amadeu; T de Oliveira Fulco; J A da Costa Nery; E P Sampaio; R O Pinheiro; E N Sarno
Journal:  Clin Exp Immunol       Date:  2011-05-18       Impact factor: 4.330

Review 5.  The continuing challenges of leprosy.

Authors:  D M Scollard; L B Adams; T P Gillis; J L Krahenbuhl; R W Truman; D L Williams
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

6.  Antigen-specific T-cell responses of leprosy patients.

Authors:  Malcolm S Duthie; Wakako Goto; Greg C Ireton; Stephen T Reece; Lucas H Sampaio; A B Grassi; Ana Lucia M Sousa; Celina M T Martelli; Mariane M A Stefani; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2008-09-10

Review 7.  Gene Association with Leprosy: A Review of Published Data.

Authors:  Priscila Saamara Mazini; Hugo Vicentin Alves; Pâmela Guimarães Reis; Ana Paula Lopes; Ana Maria Sell; Manuel Santos-Rosa; Jeane Eliete Laguila Visentainer; Paulo Rodrigues-Santos
Journal:  Front Immunol       Date:  2016-01-12       Impact factor: 7.561

8.  Serum levels of interferon-gamma, tumour necrosis factor-alpha, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions.

Authors:  A Iyer; M Hatta; R Usman; S Luiten; L Oskam; W Faber; A Geluk; P Das
Journal:  Clin Exp Immunol       Date:  2007-11       Impact factor: 4.330

9.  Increased serum levels of interleukin-6 in erythema nodosum leprosum suggest its use as a biomarker.

Authors:  Fátima Regina Vilani-Moreno; Vânia Nieto Brito-de-Souza; Sônia Maria Usó Ruiz Silva; Adriana Sierra Assêncio Almeida Barbosa; Beatriz Gomes Carreira Sartori; Ana Paula Campanelli; Jaison Antonio Barreto; Marcos da Cunha Lopes Virmond
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Mar-Apr       Impact factor: 2.545

10.  Potential plasma markers of Type 1 and Type 2 leprosy reactions: a preliminary report.

Authors:  Mariane M Stefani; Jackeline G Guerra; Ana Lucia M Sousa; Mauricio B Costa; Maria Leide W Oliveira; Celina T Martelli; David M Scollard
Journal:  BMC Infect Dis       Date:  2009-05-27       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.